Crinetics Pharmaceuticals Inc (CRNX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $84.95 (+0.13%), Market cap $4.04B, 52-week low–high $26.85 ~ $56.43.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess AC
Financial statements, price targets, institutional (13F) holdings and related news for Crinetics Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Crinetics Pharmaceuticals Inc trades at $84.95 (+0.13%). Real-time quotes and charts are available on BlackAll Trade.
Crinetics Pharmaceuticals Inc has a market cap of about $4.04B.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-r